Download PDF
Semin Thromb Hemost 2004; 30(3): 285-289
DOI: 10.1055/s-2004-831040
Copyright © 2004 by Thieme Medical Publishers, Inc., 333 Seventh Avenue, New York, NY 10001, USA.

Case Studies of HIT in Cardiovascular Medicine

Kyle J. Smith1 , 2 , Jason T. Call2 , David C. Sane2
  • 1Associate Professor of Internal Medicine, Department of Internal Medicine, Wake Forest University School of Medicine, Winston-Salem, North Carolina
  • 2Section of Cardiology, Department of Internal Medicine, Wake Forest University School of Medicine, Winston-Salem, North Carolina
Further Information

Publication History

Publication Date:
29 July 2004 (online)

    Permissions and Reprints

We present three clinical cases that illustrate some of the key features of the diagnosis and management of immune-mediated heparin-induced thrombocytopenia (HIT). The importance of having a high clinical suspicion for HIT in the appropriate clinical setting is emphasized. Early therapeutic decisions should be based on a clinical diagnosis, with laboratory tests serving as confirmation. Low-molecular-weight and unfractionated heparins are to be strictly avoided in patients with HIT. Identification bracelets or necklaces may be useful to reduce inappropriate administration of these agents to patients with HIT presenting with acute coronary syndromes.

KEYWORDS

Heparin-induced thrombocytopenia - HIT - clinical diagnosis - laboratory tests - treatment

REFERENCES

  • 1 Brieger D B, Mak K H, Kottke-Marchant K, Topol E J. Heparin-induced thrombocytopenia.  J Am Coll Cardiol. 1998;  31 1449-1459
    CrossrefPubMedSearch in Google Scholar
  • 2 Warkentin T E, Greinacher A. Heparin-Induced Thrombocytopenia. 2nd ed. New York; Marcel Dekker, Inc 2001 59
    Search in Google Scholar
  • 3 Sheth S B, DiCicco R A, Hursting M J, Montague T, Jorkasky D K. Interpreting the international normalized ratio (INR) in individuals receiving argatroban and warfarin.  Thromb Haemost. 2001;  85 435-440
    PubMedSearch in Google Scholar
  • 4 Yoder M, Edwards R F. Reversible thrombocytopenia associated with eptifibatide.  Ann Pharmacother. 2002;  36 628-630
    CrossrefPubMedSearch in Google Scholar
  • 5 Jubelirer S J, Koenig B A, Bates M C. Acute profound thrombocytopenia following C7E3 fab (abciximab) therapy: case reports, review of literature and implications for therapy.  Am J Hematol. 1999;  61 205-208
    CrossrefPubMedSearch in Google Scholar
  • 6 Warkentin T E, Kelton J G. Temporal aspects of heparin-induced thrombocytopenia.  N Engl J Med. 2001;  344 1286-1292
    CrossrefPubMedSearch in Google Scholar
  • 7 Giugliano R P. Drug-induced thrombocytopenia: is it a serious concern for glycoprotein IIb/IIIa receptor inhibitors?.  J Thromb Thrombolysis. 1998;  5 191-202
    CrossrefPubMedSearch in Google Scholar
  • 8 Warkentin T E, Levine M N, Hirsh J et al.. Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin.  N Engl J Med. 1995;  332 1330-1335
    CrossrefPubMedSearch in Google Scholar

David C SaneM.D. 

Associate Professor of Internal Medicine, Section of Cardiology, Wake Forest University School of Medicine

Medical Center Boulevard, Winston-Salem

NC 27157-1045

Email: dsane@wfubmc.edu